Chae Young Kwang, Yousaf Muhammad, Malecek Mary-Kate, Carneiro Benedito, Chandra Sunandana, Kaplan Jason, Kalyan Aparna, Sassano Antonella, Platanias Leonidas C, Giles Francis
Northwestern Medicine Developmental Therapeutics Institute, Chicago, IL 60611, USA.
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA.
Discov Med. 2015 Dec;20(112):413-27.
Statins, the most commonly prescribed class of drug, have demonstrated effects beyond cholesterol reduction including anti-tumor and immunomodulatory properties. Several epidemiological studies have suggested an anti-neoplastic effect of statins evidenced by reductions in cancer incidence and cancer-related mortality. Clinical trials on statins as part of therapy for cancer have generated interest in the oncology community. Statins have been investigated for a variety of cancers, early and late stage, and in combination with chemotherapy and radiation. So far promising results have been reported with statin use in pediatric brainstem tumors, early stage breast cancer, hepatocellular carcinoma (HCC), colorectal cancer (CRC), refractory or relapsed multiple myeloma (MM), and refractory acute myeloid leukemia (AML). There is still much investigation to be completed to determine which subtypes of patients benefit from statin therapy, how statins may potentiate other anticancer approaches, and the appropriate dosing schedule to use.
他汀类药物是最常被处方的一类药物，已显示出除降低胆固醇之外的作用，包括抗肿瘤和免疫调节特性。多项流行病学研究表明，他汀类药物具有抗肿瘤作用，表现为癌症发病率和癌症相关死亡率降低。将他汀类药物作为癌症治疗一部分的临床试验引起了肿瘤学界的兴趣。他汀类药物已针对多种癌症进行了研究，包括早期和晚期癌症，以及与化疗和放疗联合使用的情况。到目前为止，已报道他汀类药物用于小儿脑干肿瘤、早期乳腺癌、肝细胞癌（HCC）、结直肠癌（CRC）、难治性或复发性多发性骨髓瘤（MM）以及难治性急性髓细胞白血病（AML）取得了有前景的结果。仍有许多研究有待完成，以确定哪些患者亚组能从他汀类药物治疗中获益、他汀类药物如何增强其他抗癌方法以及合适的给药方案。
